文献速递胸部肿瘤

劳拉替尼相关体重增加与内脏脂肪堆积相关

Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue.
PubMed 文献 · J Thorac Oncol · 2026-07-08

该研究回顾性分析了67例接受后线劳拉替尼治疗的ALK阳性肺癌患者,利用CT评估基线及3、6、12个月的身体成分变化。结果显示内脏脂肪指数和BMI在3个月内显著增加,而皮下脂肪无充分变化证据。一例一线治疗患者3年内增重16kg并伴内脏脂肪增加,使用度拉糖肽后BMI和内脏脂肪下降。

要点

  • 劳拉替尼治疗早期即可出现内脏脂肪和BMI显著增加。
  • 体重增加以内脏脂肪堆积为主,而非皮下脂肪。
  • 未来干预应聚焦减轻内脏脂肪。

核心结论

  • 劳拉替尼治疗期间的体重增加优先与内脏脂肪堆积相关,而非皮下脂肪。

研究设计与样本

  • 回顾性分析马萨诸塞总医院前瞻性试验中67例接受后线劳拉替尼治疗的ALK阳性肺癌患者的CT图像,评估基线、3、6、12个月身体成分。

主要发现

  • 总体队列从基线到3个月,骨骼肌指数增加0.77 cm2/m2(95%CI 0.08-1.45,P=0.028),内脏脂肪指数增加4.23 cm2/m2(95%CI 2.37-6.19,P<0.001),BMI增加0.97 kg/m2(95%CI 0.59-1.35,P<0.001)。
  • 研究期间皮下脂肪指数无充分变化证据。
  • 按剂量调整后趋势持续但未达统计学显著性。
  • 一例一线劳拉替尼患者初始3年内体重增加16 kg,BMI和内脏脂肪指数增加,启动度拉糖肽后BMI和内脏脂肪指数下降。

临床怎么用

  • 接受劳拉替尼治疗的患者应关注体重和身体成分变化,尤其是内脏脂肪堆积。
  • 未来针对劳拉替尼相关体重增加的干预措施应侧重于减轻内脏肥胖。

局限性

  • 回顾性分析,样本量有限。
  • 按剂量调整后趋势未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lorlatinib exposure is associated with metabolic effects, including weight gain. Anatomical distribution (i.e., visceral versus subcutaneous) of the gained adipose tissue remains poorly characterized. METHODS: Body composition was retrospectively analyzed using computed tomography images at baseline, 3 months, 6 months, and 12 months for patients with anaplastic lymphoma kinase-positive (ALK+) lung cancer treated with later-line lorlatinib in prospective trials at the Massachusetts General Hospital. Longitudinal trends were assessed in the overall cohort and compared across lorlatinib doses. Body composition analysis was also performed for a patient receiving first-line lorlatinib. RESULTS: Between 2014 and 2020, 67 patients received lorlatinib 100 mg (n = 37) or 50 to 75 mg (n = 30). Overall, the skeletal muscle index, visceral adipose tissue index (VATI), and body mass index (BMI) increased from baseline to 3 months and from 3 months to 6 months (e.g., baseline to 3 mo skeletal muscle index: 0.77 cm2/m2 [95% confidence interval or CI: 0.08, 1.45; p value = 0.028]; VATI: 4.23 cm2/m2 [95% CI: 2.37, 6.19; p value < 0.001]; BMI: 0.97 kg/m2 [95% CI: 0.59, 1.35 kg/m2; p value < 0.001]). There was insufficient evidence of change in the subcutaneous adipose tissue index in the study period. When adjusted for dose, the trends persisted but did not reach statistical significance. Analysis of a patient receiving first-line lorlatinib reported a 16-kg weight gain and increased BMI and VATI during the initial 3 years, with a decrease in BMI and VATI after initiating dulaglutide. CONCLUSIONS: Weight gain during treatment with lorlatinib is preferentially associated with accumulation of visceral rather than subcutaneous adipose tissue. Future interventions to address lorlatinib-related weight gain should focus on mitigating visceral adiposity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Mantz L, Mercaldo ND, Peterson J, et al. Weight Gain on Lorlatinib Is Associated With Accumulation of Visceral Adipose Tissue. J Thorac Oncol. 2026. PMID: 42419484. doi:10.1016/j.jtho.2026.104078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。